- Accession Number
Agents acting to arrest the flow of blood. Absorbable hemostatics arrest bleeding either by the formation of an artificial clot or by providing a mechanical matrix that facilitates clotting when applied directly to the bleeding surface. These agents function more at the capillary level and are not effective at stemming arterial or venous bleeding under any significant intravascular pressure.
- ATC Classification
Drug Drug Description Menadione The primary known function of vitamin K is to assist in the normal clotting of blood, but it may also play a role in normal bone calcification. Tranexamic acid An antifibrinolytic agent used for heavy menstrual bleeding. Aminocaproic acid An antifibrinolytic agent used to induce clotting postoperatively. Phylloquinone A fat soluble vitamin used to treat hemorrhagic conditions in infants and coumarin overdoses. Aprotinin A serine protease inhibitor used to reduce the risk for perioperative blood loss and the need for blood transfusion in high-risk patients during cardiopulmonary bypass for coronary artery bypass graft surgery. Batroxobin No approved indications. Batroxobin is a defibrongenating agent which has been observed to reduce fibrinogen levels and thus reduce clot risk when used intravenously. Carbazochrome Indicated for capillary and parenchymal hemorrhage (trauma, tonsillectomy, during surgery), intestinal bleeding, and thrombocytopenic purpura. Thrombin A coagulation factor used to stop bleeding during surgery. Etamsylate Not Annotated Oxidized cellulose Not Annotated Calcium alginate Not Annotated Antihemophilic factor, human recombinant A form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency. Coagulation factor VIIa Recombinant Human A form of recombinant human coagulation Factor VII used to treat hemophilia A and B. Coagulation Factor IX (Recombinant) A form of recombinant human coagulation Factor IX used to treat hemophilia B. Fibrinogen human A hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia. Catridecacog A recombinant FXIII subunit‐A molecule evaluated for clotting factor replacement therapy in congenital FXIII deficiency. Susoctocog alfa A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A. Anti-inhibitor coagulant complex A medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B. Desmopressin A synthetic analog of vasopressin used to reduce renal excretion of water in central diabetes insipidus and nocturia. Vasopressin A peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy. Formic acid Formic acid (systematically called methanoic acid) is the simplest carboxylic acid. It is an important intermediate in chemical synthesis and occurs naturally, most famously in the venom of bee and... Poliglusam Poliglusam, or chitosan, is a linear polysaccharide consisting of D-glucosamine and N-acetyl-D-glucosamine. Naturally-occuring poliglusam is found in the cell walls of fungi, soil and sediments where it is produced from... Menatetrenone Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma. Aminaphthone Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction. Menaquinone 7 Menaquinone 7 is under investigation in clinical trial NCT00402974 (The Effect of Vitamin K Supplementation on Osteocalcin Carboxylation in Healthy Children). Adrenalone Not Annotated Ornipressin Not Annotated Dobesilic acid Not Annotated Naftazone Not Annotated Ferric subsulfate Ferric subsulfate is a stypic or hemostatic agent that causes agglutination of surface proteins resulting in local hemostasis. It has the chemical formula Fe4(OH)2(SO4)5. It is used after superficial skin... Bismuth subgallate A medication used to deodorize flatulence and stools as well as hemostasis in soft tissue surgery. Alpha-1-proteinase inhibitor A purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency. Romiplostim A fusion protein thrombopoietin (TPO) peptide analog that increases platelet counts by binding to and activating the human TPO receptor. Used to treat thrombocytopenia associated with chronic immune thrombocytopenia (ITP). Eltrombopag A thrombopoietin receptor agonist used to treat thrombocytopenia or aplastic anemia associated with various etiologies. Von Willebrand Factor Human A complex of von Willebrand Factor and Factor VIII used to treat bleeding episodes in von Willebrand disease. Coagulation factor X human A coagulation factor used to treat Factor X deficiency to control bleeding. Antihemophilic factor human A Factor VIII replacement therapy used to treat hemophilia A. Aminomethylbenzoic acid Aminomethylbenzoic acid may be useful as an antifibrinolytic agent . Tetragalacturonic acid hydroxymethylester Not Annotated Camostat Not Annotated Turoctocog alfa An antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency). Antihemophilic Factor (Recombinant), PEGylated For the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)... Thrombin alfa A platelet activating factor used to treat minor bleeding. Efmoroctocog alfa A recombinant Factor VIII used to treat and prevent bleeding in hemophilia A. Eftrenonacog alfa A recombinant Factor IX used to treat and prevent bleeding in hemophilia B. Factor XIII (human) A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency. Coagulation Factor IX Human A coagulation factor used to treat hemophilia B or factor IX hemophilia. Albutrepenonacog alfa A recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B. Nonacog beta pegol A recombinant coagulation Factor IX derivative used to treat hemophilia B. Plasma protein fraction (human) A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures. Lonoctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Moroctocog alfa A recombinant Factor VIII used to treat hemophilia A to control bleeding. Epinephrine A hormone and neurotransmitter used to treat allergic reactions, to restore cardiac rhythm, and to control mucosal congestion, glaucoma, and asthma. Potassium triiodide Not Annotated Lypressin Not Annotated Turoctocog alfa pegol Turoctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of... Avatrombopag A thrombopoietin receptor agonist used to treat thrombocytopenia in patients with chronic liver disease who are scheduled to undergo a procedure. Fostamatinib A spleen tyrosine kinase inhibitor used to treat chronic immune thrombocytopenia after attempting one other treatment. Lusutrombopag A medication used to treat thrombocytopenia in patients with chronic liver disease scheduled to have a procedure. Emicizumab An antibody against Factor IXa and Factor X used to treat hemophilia A. Menaquinone 6 Menaquinone 6 is under investigation in clinical trial NCT01194778 (Comparison of Efficacy of Different Dosages Vitamin K2). Menaquinone Menaquinone is under investigation in clinical trial NCT01533441 (Vitamin K2 Intervention in Patients With Vitamin K Antagonists).
- Drugs & Drug Targets